Hernán A. Feola, Servicio de Dermatología, Hospital Interzonal Especializado de Agudos y Crónicos “San Juan de Dios de La Plata”, La Plata, Argentina
Lucía M. Córdoba, Servicio de Dermatología, Hospital Interzonal Especializado en Agudos y Crónicos San Juan de Dios de La Plata, La Plata, Argentina
María C. Mancinelli, Servicio de Dermatología, Hospital Interzonal Especializado en Agudos y Crónicos San Juan de Dios de La Plata, La Plata, Argentina
Yolanda L. Giménez, Servicio de Dermatología, Hospital Interzonal Especializado en Agudos y Crónicos San Juan de Dios de La Plata, La Plata, Argentina
Mercedes L. Bertolotti, Departamento de Docencia de la Cátedra de Dermatología, Facultad de Ciencias Médicas, Universidad Nacional de La Plata (UNLP). La Plata, Argentina
,
Melasma is a melanic dyschromia with hyperpigmentation, with poorly delimited edges, which affects photo-exposed areas, mainly the face, in people with phototypes III and IV. The basic management is based on avoiding exposure to UV radiation and treatment with combined topical therapy (hydroquinone 2-4%, retinoids and corticoids). Despite this, melasma is usually refractory or difficult to manage. Oral tranexamic acid is a relatively new therapy that has been shown to be effective in clinical trials and should be considered in certain circumstances for this type of patient. We present a patient with melasma refractory to first line therapies, treated with tranexamic acid (TA) orally as monotherapy, with a considerable decrease in mMASI at 3 months and a review of the bibliography available to date about this treatment.
Keywords: Tranexamic acid. Refractory melasma. Facial pigmentations